Shares of FibroGen Inc. (NASDAQ:FGEN) shot up 2.2% during trading on Friday . The stock traded as high as $17.13 and last traded at $17.03, with a volume of 261,699 shares changing hands. The stock had previously closed at $16.66.

Several brokerages have commented on FGEN. Credit Suisse Group AG reissued a “buy” rating on shares of FibroGen in a report on Wednesday, May 25th. Zacks Investment Research lowered FibroGen from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. FibroGen presently has an average rating of “Buy” and a consensus target price of $33.50.

The firm’s 50-day moving average is $17.14 and its 200-day moving average is $19.22. The stock’s market cap is $1.07 billion.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.11. Analysts expect that FibroGen Inc. will post ($1.02) EPS for the current year.

In related news, CEO Thomas B. Neff sold 13,500 shares of the stock in a transaction on Tuesday, April 19th. The stock was sold at an average price of $20.21, for a total value of $272,835.00. Following the transaction, the chief executive officer now directly owns 3,579,353 shares of the company’s stock, valued at approximately $72,338,724.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas B. Neff sold 27,000 shares of the stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $17.78, for a total value of $480,060.00. Following the completion of the transaction, the chief executive officer now directly owns 3,552,353 shares in the company, valued at $63,160,836.34. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors raised its position in shares of FibroGen by 0.8% in the fourth quarter. Nationwide Fund Advisors now owns 51,597 shares of the biopharmaceutical company’s stock valued at $1,572,000 after buying an additional 393 shares during the period. ProShare Advisors LLC purchased a new position in shares of FibroGen during the fourth quarter valued at $1,715,000. California State Teachers Retirement System raised its position in shares of FibroGen by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 88,701 shares of the biopharmaceutical company’s stock valued at $2,703,000 after buying an additional 1,400 shares during the period. Rhumbline Advisers raised its position in shares of FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock valued at $1,400,000 after buying an additional 3,675 shares during the period. Finally, Swiss National Bank raised its position in shares of FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock valued at $1,932,000 after buying an additional 1,100 shares during the period.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.